Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Drugs in the Pipeline

Trial Assessing Atezolizumab in Triple-Negative Breast Cancer Misses End Point

Brian Park, PharmD

August 7, 2020

Findings showed that the study did not meet statistical significance for progression free survival.

News

Blenrep Approved for Relapsed/Refractory Multiple Myeloma

Brian Park, PharmD

August 7, 2020

Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F.

Drugs in the Pipeline

NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19

Brian Park, PharmD

August 6, 2020

The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.

News

FDA: Drug “In-Use Time” May Be Extended in Certain Cases

Brian Park, PharmD

August 6, 2020

has provided guidance to healthcare facilities and providers looking to use certain drugs beyond their labeled “in-use times” due to supply issues related to the coronavirus disease 2019 (COVID-19) pandemic.

Drugs in the Pipeline

Novavax’s Adjuvanted COVID-19 Vaccine Candidate Promising in Early Trial

Brian Park, PharmD

August 6, 2020

The vaccine candidate contains the Company’s saponin-based Matrix-M™ adjuvant technology to enhance immune response.

News

EyeArt Autonomous AI System Cleared for Diabetic Retinopathy Screening

Brian Park, PharmD

August 6, 2020

EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.

Drugs in the Pipeline

Sisunatovir Fast-Tracked for Serious RSV Infection

Brian Park, PharmD

August 6, 2020

Sisunatovir is an orally administered RSV fusion inhibitor that binds to RSV-F protein on the viral surface inhibiting RSV replication.

News

Spravato Approved for MDD With Acute Suicidal Ideation or Behavior

Brian Park, PharmD

August 5, 2020

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

News

Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema

Brian Park, PharmD

August 5, 2020

Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that blocks the activation of the JAK-STAT pathway.

News

FDA Wants More Data on Viaskin Peanut Allergy Patch

Brian Park, PharmD

August 5, 2020

The FDA noted that it could not approve the BLA due to concerns regarding “the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study.”